摘要
Incomplete tumor ablation and subsequent tumor metastasis usually occur during photothermal anti-tumor processes. The combination of photothermal and immunotherapy has proven to be a promising method to conquer technical challenges. Inhibiting the programmed death ligand-1 (PD-L1)/programmed cell death protein 1 (PD-1) immune pathway represents one of the most successful immunotherapy strategies. Whereas, the PD-L1 expression level significantly differs, leading to a relatively low response rate to the immune checkpoint blockade (ICB) approaches. Therefore, improving the expression level of PD-L1 becomes one potential method to enhance the response rate. Herein, NIH 3T3 cells were educated to steadily express PD-1 protein. Furthermore, the synthesized molybdenum nitride was then coated with PD-1 protein-modified cytomembrane, which endows it with immune checkpoint blocking capability. Moreover, under the irradiation of near-infrared light, the local mild heat released from the molybdenum nitride causes the apoptosis of tumor cells. More importantly, the elevated temperature simultaneously helps elevate the expression level of PD-L1, further enhancing the response rate of ICB. Finally, the PD-1 cytomembrane coatings interact with the upregulated PD-L1, leading to the activation of the immune system. In summary, we confirmed that the PD-1 protein-coated molybdenum nitride could synergistically ablate tumors and avoid metastasis.
学科与关键词
- Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapyYin, Shuangneng; Chen, Zhaojun; Chen, Dugang*; Yan, Dan*2023, 13(5): 1520-1544.被引 16
- Combining PD-L1 inhibitors with immunogenic cell death triggered by chemo-photothermal therapy via a thermosensitive liposome system to stimulate tumor-specific immunological responseYu, Jie; He, Xidong; Wang, Zigui; Wang, Yupeng; Liu, Sha; Li, Xiaoyuan*; Huang, Yubin*Nanoscale, 2021, 13(30): 12966-12978.被引 32
- Near-Infrared-II Nanoparticles for Cancer Imaging of Immune Checkpoint Programmed Death-Ligand 1 and Photodynamic/Immune TherapyLiu, Qiang; Tian, Jiangwei; Tian, Ye; Sun, Qinchao; Sun, Dan; Wang, Feifei; Xu, Haijun*; Ying, Guoliang*; Wang, Jigang*; Yetisen, Ali K.; Jiang, Nan*ACS Nano, 2021, 15(1): 515-525.被引 80
